Agid, Y., Javoy-Agid, F. & Ruberg, M. (1987) Biochemistry of neurotransmitters in Parkinson's disease. In Movement Disorders 2 (eds Marsden, C. D. & Fahn, S.), pp. 166–230. London: Butterworths.
Ansseau, M., Von Frenckell, R., Cerfontaine, J. L., et al (1988) Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. British Journal of Psychiatry, 153, 65–71.
Birkmayer, W., Danielczyk, W., Neumayer, E., et al (1974) Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings. Journal of Neural Transmission, 35, 93–116.
Brown, R. G. & MacCarthy, B. (1990) Psychiatric morbidity in patients with Parkinson's disease. Psychological Medicine, 20, 77–87.
Canter, C. J., De La Torre, R. & Mier, M. A. (1961) A method of evaluating disability in Parkinson's disease. Journal of Nervous and Mental Disease, 133, 143–147.
Cheng, A. V. T., Ferrier, I. N., Morris, C. M., et al (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's disease and Parkinson's diseases. Journal of the Neurological Sciences, 106, 50–55.
Corn, T., Hale, A. S., Thompson, C., et al (1984) A comparison of the GH responses to clonidine and apomorphine in the same endogenously depressed patients. British Journal of Psychiatry, 144, 636–639.
Cummings, J. L. (1992) Neuropsychiatric complications of drug treatment of Parkinson's disease. In Parkinson's Disease. Neurobehavioural Aspects (eds Huber, S. J. & Cummings, J. L.), pp. 313–327. Oxford: Oxford University Press.
Ferrier, I. N., Johnstone, E. C. & Crow, T. J. (1984) Hormonal effects of apomorphine in schizophrenia. British Journal of Psychiatry, 144, 349–357.
Folstein, M. F., Folstein, S. E. & McHugh, P. R. (1975) Mini-Mental State Examination. Journal of Psychiatric Research, 12, 189–198.
Gibb, W. R. G. & Lees, A. J. (1988) The relevance of the Lewy body to the pathogenesis of Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry, 51, 745–752.
Hoehn, M. M. & Yahr, M. D. (1967) Parkinsonism: onset, progression and mortality. Neurology, 17, 427–442.
Jimerson, D. C., Cutler, N. R., Post, R. M., et al (1984) Neuroendocrine responses to apomorphine in depressed and healthy control subjects. Psychiatry Research, 13, 1–12.
Klawans, H. L., Goetz, C., Nausieda, P. A., et al (1977) Levodopa-induced dopamine receptor hypersensitivity. Annals of Neurology, 2, 125–129.
Pitchot, W., Ansseau, M., Moreno, A. G., et al (1992) Dopaminergic function in panic disorder: comparison with major and minor depression. Biological Psychiatry, 32, 1004–1011.
Sadzot, B., Baraban, J. M., Glennon, R. A., et al (1989) Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology, 98, 495–499.
Stein, M. B., Heuser, I. J., Juncos, J. L., et al (1990) Anxiety disorders in patients with Parkinson's disease. American Journal of Psychiatry, 147, 217–220.
Webster, D. D. (1968) Critical analysis of the disability in Parkinson's disease. Modern Treatments, 5, 257–282.
Wieck, A., Kumar, R., Hirst, A. D., et al (1991) Increased sensitivity of dopamine receptors and recurrence of affective psychosis after childbirth. British Medical Journal, 303, 613–616.
Wing, J. K., Cooper, J. E. & Sartorius, N. (1973) The Measurement and Classification of Psychiatric Symptoms. An Instruction for the Present State Examination and Catego Program.
Cambridge: Cambridge University Press.
Zemlan, F. P., Hirschowitz, J. & Garver, D. L. (1986) Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients. Archives of General Psychiatry, 43, 1162–1167.